➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Merck
Boehringer Ingelheim
McKesson
AstraZeneca

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Suramin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Suramin?

Suramin is an investigational drug.

There have been 20 clinical trials for Suramin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 1996.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Prostatic Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Southwest Oncology Group, and Eastern Cooperative Oncology Group.

Recent Clinical Trials for Suramin
TitleSponsorPhase
Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant AKIRediscovery Life SciencesPhase 2
Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei RhodesienseEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Phase 2/Phase 3
Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei RhodesienseDrugs for Neglected DiseasesPhase 2/Phase 3

See all Suramin clinical trials

Clinical Trial Summary for Suramin

Top disease conditions for Suramin
Top clinical trial sponsors for Suramin

See all Suramin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Merck
Boehringer Ingelheim
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.